GALAPAGOS NV/S (NASDAQ:GLPG) had its price objective raised by HC Wainwright to $150.00 in a research report sent to investors on Friday, March 29th. HC Wainwright currently has a positive rating on the biotechnology company’s stock.
A number of other research analysts have also issued reports on the company. BidaskClub upgraded GALAPAGOS NV/S from a hold rating to a buy rating in a research report on Friday, January 11th. ValuEngine upgraded GALAPAGOS NV/S from a hold rating to a buy rating in a research report on Friday, March 1st. Credit Suisse Group upgraded GALAPAGOS NV/S from a neutral rating to an outperform rating in a research report on Thursday, December 13th. Cantor Fitzgerald started coverage on GALAPAGOS NV/S in a research report on Wednesday, December 19th. They set an overweight rating and a $130.00 price objective for the company. Finally, Svb Leerink began coverage on GALAPAGOS NV/S in a research report on Friday, February 22nd. They set an outperform rating for the company. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, eleven have issued a buy rating and two have issued a strong buy rating to the stock. The company currently has a consensus rating of Buy and an average target price of $125.83.
Shares of NASDAQ:GLPG opened at $115.43 on Friday. GALAPAGOS NV/S has a one year low of $85.00 and a one year high of $125.48. The stock has a market cap of $5.91 billion, a P/E ratio of -43.72 and a beta of 1.68.
GALAPAGOS NV/S Company Profile
Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes novel medicines. Its clinical stage programs include filgotinib, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and Crohn's disease, Phase 2/3 trials for ulcerative colitis, and Phase II trials for multiple additional indications; GLPG1690, an autotaxin inhibitor, which is in Phase III clinical trial for the treatment of idiopathic pulmonary fibrosis; GLPG1972 that completed Phase 1b clinical trial for the treatment of osteoarthritis; and MOR106, which is in Phase II trials for atopic dermatitis patients.
Further Reading: What is the S&P 500 Index?
Receive News & Ratings for GALAPAGOS NV/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GALAPAGOS NV/S and related companies with MarketBeat.com's FREE daily email newsletter.